Market data loadingS&P 500--NASDAQ--Data as of latest ETNo timestamp

NeuroPace, Inc. (NPCE) Institutional Ownership & Insider Trading

113 institutions reported holding NeuroPace, Inc. shares in 13F filings for the quarter ended 2026-06-30, according to EquiReason's reading of their SEC filings. 1 insider trades on Form 4 since 2025-10-01.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

NPCENeuroPace, Inc.Follow NPCE — free
Medical Devices · Healthcare
—
Price chart with a free account
Market cap
443.1M
P/E TTM
—
Dividend yield
0.0%
52-week
—
Next earnings
10 Nov, in 17 days

Institutions · all 13F filers

quarter to 30 Jun 2026 · filers in both quarters

113 institutions held 77.4% of the shares. Across filers that reported both quarters, shares held changed +0.1%.

Increased+45New+14Decreased-32Closed-15

Largest moves, shares (millions)

First Light Asset Management+0.4MBlackRock+0.1MD. E. Shaw+0.1MOrbimed Advisors-0.6MPoint72 Asset Management-0.2MTopline Capital Management-0.1M

Institutional flow by quarter

net shares added or trimmed, millions · filers in both quarters
-2.8Sep 24+0.8Dec 24+8.2Mar 25-1.3Jun 25+3.5Sep 25+0.7Dec 25+0.8Mar 26+0.0Jun 26
QuarterHoldersShares held, MChangeIncreasedNewDecreasedClosed
Jun 2611327+0.1%45143215
Mar 2611226+3.3%36233610
Dec 259926+3.0%3424274
Sep 258026+15.5%3181825
Jun 259823-5.6%42212110
Mar 259024+52.8%2731133
Dec 246221+5.3%191474
Sep 244815-18.2%135138

NeuroPace, Inc. — questions

Who owns NeuroPace, Inc. stock?
113 institutions reported NeuroPace, Inc. shares in 13F filings for the quarter ended 2026-06-30. The largest: Polar Capital Holdings Plc (9.6%), Soleus Capital Management, L.P. (8.5%), First Light Asset Management, LLC (8.3%).
Are NeuroPace, Inc. insiders buying or selling?
1 insider trades on Form 4 since 2025-10-01; the full list, with dates, people and plan status, is on this page.

Every figure on this page comes from NeuroPace, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.